Next 10 |
home / stock / kymr / kymr articles
KT-253 demonstrates initial clinical proof of concept in patients with tumor types shown to be sensitive in preclinical models, including response...
WATERTOWN, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing...
Abstract released today highlights safety, pharmacodynamic and clinical response data with additional data to be presented in a poster session on ...
Abstract released today highlights safety, pharmacodynamic and clinical response data collected through February 6, 2024 cut-off date Updated data...
WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing...
WATERTOWN, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advanci...
WATERTOWN, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancin...
WATERTOWN, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancin...
INVO (NASDAQ: INVO) and NAYA Biosciences expect to close their previously announced merger in the first quarter of 2024 Experienced, entrepreneu...
News, Short Squeeze, Breakout and More Instantly...
Kymera Therapeutics Inc. Company Name:
KYMR Stock Symbol:
NASDAQ Market:
Kymera Therapeutics Inc. Website:
PALM BEACH, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Pancreatic cancer is among the most frequently diagnosed and the seventh leading cause of cancer death globally. Pancreatic cancer becomes more common in the Western world. The prevalence rate of panc...
KT-333 demonstrated initial clinical proof of concept across multiple hematological malignancies, including complete responses in two patients with Hodgkin’s lymphoma Robust STAT3 knockdown and positive immunomodulatory effect achieved in blood and tumor KT-333 was well-t...
KT-253 demonstrates initial clinical proof of concept in patients with tumor types shown to be sensitive in preclinical models, including responses in MCC and AML Evidence of target engagement and potent upregulation of p53 pathway biomarkers even at the lowest dose levels in solid tumo...